Related Experiment Videos
Thyroid hormones in differentiated thyroid cancer
A M Samuel1, M N Mehta, K B Desai
1Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre Annexe, Parel, Bombay.
Clinical Nuclear Medicine
|January 1, 1994
Summary
Radioiodine therapy effectiveness in differentiated thyroid cancer varies. Patients with functioning metastases and normal hormone levels showed poor response, while those with low thyroglobulin and hormone synthesis responded better.
Area of Science:
- Endocrinology
- Nuclear Medicine
- Oncology
Background:
- Differentiated thyroid cancer (DTC) management often involves radioiodine therapy.
- Predicting treatment response in metastatic DTC remains a clinical challenge.
- Thyroglobulin (Tg) levels and hormone synthesis by metastases are potential biomarkers.
Purpose of the Study:
- To evaluate the impact of metastatic disease characteristics on radioiodine therapy outcomes in differentiated thyroid cancer.
- To investigate the relationship between thyroglobulin levels, hormone synthesis, and treatment response.
Main Methods:
- Retrospective analysis of 136 differentiated thyroid cancer patients undergoing radioiodine therapy since 1991.
- Assessment of metastatic disease, thyroglobulin levels, and evidence of thyroid hormone synthesis.
- Correlation of these factors with patient response to radioiodine treatment.
Main Results:
- 80 of 136 patients had metastatic disease; 51 had elevated thyroglobulin (Tg).
- 15 patients had functioning metastases; 14 were follicular carcinomas with skeletal metastases and poor radioiodine response.
- Patients with high Tg but low hormone synthesis, and those with low Tg and low hormone synthesis, showed better radioiodine response.
Conclusions:
- Functioning metastases with normal circulating hormone levels predict poor radioiodine therapy response in DTC.
- Elevated Tg with low hormone synthesis, and low Tg with low hormone synthesis, indicate better radioiodine uptake and treatment efficacy.
- Radioiodine therapy outcomes in metastatic DTC are influenced by tumor characteristics and functional status.